ID Practice Update

Short lecture / 10-20 minutes

An OPAT primer

What must be settled before discharge on IV antibiotics?

A discharge date does not settle whether IV treatment is still necessary, where it can be delivered, or who will act on the next result.

Resident discussion / Optional fellow section / Edited November 10, 2026

Optional fellow discussion is below

The short resident lecture comes first. Jump directly to the fellow discussion for additional detail.

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

Decide whether the patient needs outpatient IV treatment

A 59-year-old is improving after drainage of an infection. The team requests a PICC for discharge tomorrow. Final susceptibilities are pending, the intended duration is not documented, and no outpatient clinician has agreed to review and act on results after discharge.

Discuss before reading on. Which decisions are still missing? Would placing the line solve any of them?

This lecture concerns outpatient parenteral antimicrobial therapy (OPAT) delivered intravenously. The decision begins with the infection, what remains after source control, and the intended treatment course. If an oral agent is active, reaches the infected site, and can be taken and absorbed reliably without unacceptable interactions, a line may offer no advantage. Clinical improvement alone does not answer those questions. [1] [2]

Match the plan to both the infection and the patient

Discharge planning includes the patient and the receiving team.
QuestionWhat must be established
Is the patient ready?Clinical stability, a source-control plan, and no unresolved need for inpatient care.
Can the regimen be delivered?Home, infusion-center, or facility capacity; caregiver ability when needed; training, transport, supplies, and cost.
Is the prescription appropriate?Drug, dose, interval, infusion method, renal adjustment, and a defined duration based on the infection.
Who will manage problems?An identified clinician or service accepts follow-up. The patient and receiving team know whom to reach for missed doses, catheter problems, and adverse effects.

A clinic that opens once daily cannot deliver every hospital regimen. The relevant questions are whether an alternative provides the exposure the infection requires and whether the preparation remains stable in the proposed pump. The receiving pharmacy helps resolve both before the plan is accepted. [2]

Choose vascular access after choosing the treatment

A midline may suit an adult who needs less than 14 days of OPAT with a peripherally compatible drug, although evidence for that cutoff is limited. In advanced chronic kidney disease, a PICC can compromise arm veins needed for future dialysis access. When central access is necessary, a tunneled central catheter is preferred; the nephrology and vascular-access teams can help assess the options. [1]

Avoid routine midline use for vancomycin OPAT. In a retrospective cohort of patients with midlines, vancomycin was associated with more major device complications than other antibiotics (adjusted hazard ratio 4.82, 95% CI 2.64 to 8.83). The separate cohort comparing midlines with PICCs found fewer major device complications with midlines, particularly at 14 days or less, and excluded vancomycin. The relative safety of a PICC versus a midline for vancomycin remains uncertain. The 2018 IDSA guideline left central access optional for vancomycin (weak recommendation, very low-quality evidence) and predates these studies. Consider other agents or access options with the OPAT and vascular-access teams, especially when kidney disease affects access planning. [1] [7] [8]

When a catheter has been removed for S. aureus catheter-related bloodstream infection and new access is needed, the 2009 guidance permits placement once additional blood cultures show no growth. It does not specify a fixed interval that applies to all bloodstream infections. [3]

A catheter should come out promptly once it is no longer needed. Naming the person responsible for removal helps prevent a line from remaining solely because follow-up was overlooked. [4]

Who sees an abnormal result, and who acts?

Monitoring during outpatient IV therapy
TreatmentMonitoring considerations
Most IV regimensBaseline blood counts, renal function, relevant chemistries, and liver tests when appropriate give later changes context. The drug, duration, interacting medications, and clinical course determine which tests need repeating.
VancomycinRenal function, dose history, and sample timing are needed to interpret a vancomycin level. For serious MRSA infection, the usual AUC24 target is 400–600 mg·h/L when the broth-microdilution MIC is assumed to be 1 mg/L. A trough of 15–20 mg/L alone is not the target for this indication. [6]
DaptomycinBaseline CK and at least weekly CK measurements help detect muscle toxicity. In adults with renal impairment, both CK and renal function need monitoring more often than weekly. Recent or concurrent statin therapy, rising CK, or new muscle pain or weakness calls for closer assessment. [5]
Any regimen with changing renal function or new symptomsReassess promptly. Do not wait for the next routine weekly laboratory draw.

U.S. guidance calls for serial testing but does not establish a schedule for each drug. UK good practice recommends blood tests at least weekly during IV OPAT, including blood counts, renal and liver function, C-reactive protein, and drug levels where appropriate. Neither approach makes it safe to defer assessment of new symptoms or changing renal function until the next scheduled draw. [1] [2]

Daptomycin can cause eosinophilic pneumonia. New fever, dyspnea, hypoxemia or pulmonary infiltrates require prompt evaluation. If this syndrome is suspected, stop daptomycin immediately; labeling recommends systemic corticosteroid treatment. Do not wait for the next scheduled OPAT assessment. [5]

What the receiving team needs at handoff

The handoff explains what is being treated, the organism and source control to date, and why the chosen route is needed. The receiving team needs the actual drug, dose, interval and infusion method, the start and stop or review dates, and the access and line-care plan. For each pending study or scheduled test, who receives the result, when is it due, and who acts? Follow-up, urgent contact, and responsibility for catheter removal should be clear to the patient as well as the team. [1] [2]

A patient or caregiver can demonstrate administration and line care and explain whom they would contact for a missed infusion, rigors, catheter-site inflammation, arm swelling, or a rash. Severe symptoms, including respiratory distress, require emergency evaluation rather than a routine callback. [2] [4] [5]

In the opening case, drainage and improvement make oral treatment worth assessing, but do not establish it. If susceptibility results are still pending at discharge, the interim regimen needs a clinical rationale, and an identified clinician must agree to review the result and change therapy if needed. The team still has to establish the treatment endpoint. Placing a PICC resolves none of these questions. [1] [2]

Apply this on the next consult

Three questions close the discussion. Does this infection still need IV treatment? Can this patient and the receiving service deliver it safely? Who follows results, reassesses the endpoint, and arranges removal of the line once it is no longer needed?

The receiving service must be able to deliver the agreed plan

Review the actual infusion schedule with the receiving pharmacy or facility. A hospital prescription does not establish home-drug stability, refrigeration needs, pump compatibility, or nursing availability. Include the patient in choosing a feasible setting. [2]

Evidence does not support a general recommendation for or against home OPAT for people who inject drugs. For an individual patient, can treatment be given safely at home with the available support? The discussion includes the patient’s preferences, access to addiction care, and other feasible treatment settings. [1]

Oral therapy and long-acting IV agents can reduce access burdens in selected infections, but each still requires a defined indication, monitoring, and follow-up. They are not substitutes for source control or review of the supporting infection-specific evidence. [2]

Discussion variation. The home nurse reports a substantial creatinine increase during vancomycin treatment. This needs same-day clinical review. The clinician responsible for therapy and the supporting pharmacist need the creatinine trend, recent doses, and sample times to determine the next dose or test. The patient and infusion service need the decision before the next planned infusion. A weekly schedule for a stable patient does not answer who will act on today’s result. [1] [2] [6]

Sources and further reading

1. Norris AH, et al. IDSA OPAT guideline. 2018.

2. Noble AL, et al. Updated UK OPAT good practice recommendations. JAC Antimicrob Resist. 2026.

3. Mermel LA, et al. IDSA intravascular catheter-related infection guideline. 2009 (archived; update in progress).

4. CDC. Prevention of intravascular catheter-related infections, summary recommendations.

5. CUBICIN prescribing information. Myopathy, renal impairment, and eosinophilic pneumonia. FDA label, sections 5.2–5.3.

6. Rybak MJ, et al. ASHP/IDSA/PIDS/SIDP consensus guideline for vancomycin monitoring in serious MRSA infection. Published March 19, 2020.

7. Paje D, et al. Midline vs peripherally inserted central catheter for OPAT. JAMA Intern Med. 2025;185:83–91.

8. Paje D, et al. Safety of vancomycin use through midline catheters for OPAT. JAMA Intern Med. 2025;185:1162–1164.

Teaching cases are fictional.